Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo.
Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated measures.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All patients who are eligible for Ocrelizumab therapy based on FDA criteria
You may not be if
All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests.
